3 results
1. To assess tolerability and safety of BAX 826 after a single infusion in previously PTPs with severe hemophilia A.2. To determine the pharmacokinetic (PK) parameters of BAX 826 compared to ADVATE.3. To evaluate the impact of anti- PSA antibodies…
The primary objective is to compare the Vanguard XP with a CR TKA in terms of kinematics during functional tests using 3D fluoroscopy. The secondary objective is to compare both TKAs in terms of 3D migration of the prosthesis up until 2 years post-…
The primary objective is progression-free survival (PFS); defined as the time from randomization to the date of the first documented tumor progression; determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or death due…